Gilead Sciences, Inc. which can be found using ticker (GILD) now have 27 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $126.00 and $82.00 suggesting an average analyst share price target price of $107.03. (at the time of writing). Given that the stocks previous close was at $105.25 this would indicate that there is a potential upside of 1.7%. The 50 day MA is $94.49 and the 200 moving average now moves to $81.74. The market capitalization for the company is 134.16B. The current share price for the company is: $107.65 USD
The potential market cap would be $136,435,099,161 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 283.29, revenue per share of $23.06 and a 11.22% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
